Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 629

1.

Cancer Stem Cell Biomarkers in EGFR-Mutation-Positive Non-Small-Cell Lung Cancer.

Codony-Servat J, Codony-Servat C, Cardona AF, Giménez-Capitán A, Drozdowskyj A, Berenguer J, Bracht JWP, Ito M, Karachaliou N, Rosell R.

Clin Lung Cancer. 2019 Feb 21. pii: S1525-7304(19)30024-5. doi: 10.1016/j.cllc.2019.02.005. [Epub ahead of print]

PMID:
30885551
2.

Association between the novel classification of lung adenocarcinoma subtypes and EGFR/KRAS mutation status: A systematic literature review and pooled-data analysis.

Jiang L, Mino-Kenudson M, Roden AC, Rosell R, Molina MÁ, Flores RM, Pilz LR, Brunelli A, Venuta F, He J; AME Lung Cancer Collaborative Group.

Eur J Surg Oncol. 2019 Feb 16. pii: S0748-7983(19)30275-6. doi: 10.1016/j.ejso.2019.02.006. [Epub ahead of print]

PMID:
30833014
3.

A Single-Center Retrospective Study of Patients with Double Primary Cancers: Breast Cancer and EGFR-Mutant Non-Small Cell Lung Cancer.

Moran T, Quiroga V, Cirauqui B, Vila L, Gil-Moreno M, Carcereny E, Margeli M, Muñoz-Marmol A, Mate JL, Velarde JM, Molina MA, Rosell R.

Oncol Res Treat. 2019;42(3):107-114. doi: 10.1159/000495666. Epub 2019 Feb 23.

PMID:
30799393
4.

A comprehensive analysis of factors related to carmustine/bevacizumab response in recurrent glioblastoma.

Cardona AF, Rojas L, Wills B, Ruiz-Patiño A, Abril L, Hakim F, Jiménez E, Useche N, Bermúdez S, Mejía JA, Ramón JF, Carranza H, Vargas C, Otero J, Archila P, Rodríguez J, Rodríguez J, Behaine J, González D, Jacobo J, Cifuentes H, Feo O, Penagos P, Pineda D, Ricaurte L, Pino LE, Vargas C, Marquez JC, Mantilla MI, Ortiz LD, Balaña C, Rosell R, Zatarain-Barrón ZL, Arrieta O.

Clin Transl Oncol. 2019 Feb 23. doi: 10.1007/s12094-019-02066-2. [Epub ahead of print]

PMID:
30798512
5.

Evaluation of the effectiveness of the SurePure Turbulator ultraviolet-C irradiation equipment on inactivation of different enveloped and non-enveloped viruses inoculated in commercially collected liquid animal plasma.

Blázquez E, Rodríguez C, Ródenas J, Navarro N, Riquelme C, Rosell R, Campbell J, Crenshaw J, Segalés J, Pujols J, Polo J.

PLoS One. 2019 Feb 21;14(2):e0212332. doi: 10.1371/journal.pone.0212332. eCollection 2019.

6.

Biological therapies in lung cancer treatment: using our immune system as an ally to defeat the malignancy.

Filipska M, Pedraz-Valdunciel C, Chaib I, Rosell R.

Expert Opin Biol Ther. 2019 Feb 14:1-11. doi: 10.1080/14712598.2019.1582635. [Epub ahead of print]

PMID:
30763126
7.

Characteristics and long-term outcomes of advanced pleural mesothelioma in Latin America (MeSO-CLICaP).

Rojas L, Cardona AF, Trejo-Rosales R, Zatarain-Barrón ZL, Ramírez-Tirado LA, Ruiz-Patiño A, Campos Gómez S, Corrales L, Oblitas G, Bacon L, Martín C, de Lima VCC, Freitas HC, Mas L, Vargas C, Carranza H, Otero J, Pérez MA, González L, Chirinos L, Granados ST, Rodriguez J, Báez R, Remolina Bonilla YA, Núñez Cerrillo G, Archila P, Cuello M, Karachaliou N, Rosell R, Arrieta O; on behalf CLICaP.

Thorac Cancer. 2019 Mar;10(3):508-518. doi: 10.1111/1759-7714.12967. Epub 2019 Jan 31.

8.

Tumor mutational burden as predictive factor of response to immunotherapy.

Gonzalez-Cao M, Viteri S, Karachaliou N, Aguilar A, García-Mosquera JJ, Rosell R.

Transl Lung Cancer Res. 2018 Dec;7(Suppl 4):S358-S361. doi: 10.21037/tlcr.2018.10.03. No abstract available.

9.

Deep learning using tumor HLA peptide mass spectrometry datasets improves neoantigen identification.

Bulik-Sullivan B, Busby J, Palmer CD, Davis MJ, Murphy T, Clark A, Busby M, Duke F, Yang A, Young L, Ojo NC, Caldwell K, Abhyankar J, Boucher T, Hart MG, Makarov V, Montpreville VT, Mercier O, Chan TA, Scagliotti G, Bironzo P, Novello S, Karachaliou N, Rosell R, Anderson I, Gabrail N, Hrom J, Limvarapuss C, Choquette K, Spira A, Rousseau R, Voong C, Rizvi NA, Fadel E, Frattini M, Jooss K, Skoberne M, Francis J, Yelensky R.

Nat Biotechnol. 2018 Dec 17. doi: 10.1038/nbt.4313. [Epub ahead of print]

PMID:
30556813
10.

Differential Subcellular Localization Regulates Oncogenic Signaling by ROS1 Kinase Fusion Proteins.

Neel DS, Allegakoen DV, Olivas V, Mayekar MK, Hemmati G, Chatterjee N, Blakely CM, McCoach CE, Rotow JK, Le A, Karachaliou N, Rosell R, Riess JW, Nichols R, Doebele RC, Bivona TG.

Cancer Res. 2019 Feb 1;79(3):546-556. doi: 10.1158/0008-5472.CAN-18-1492. Epub 2018 Dec 11.

PMID:
30538120
11.

Universal screening for Lynch syndrome in a large consecutive cohort of Chinese colorectal cancer patients: High prevalence and unique molecular features.

Jiang W, Cai MY, Li SY, Bei JX, Wang F, Hampel H, Ling YH, Frayling IM, Sinicrope FA, Rodriguez-Bigas MA, Dignam JJ, Kerr DJ, Rosell R, Mao M, Li JB, Guo YM, Wu XY, Kong LH, Tang JH, Wu XD, Li CF, Chen JR, Ou QJ, Ye MZ, Guo FM, Han P, Wang QW, Wan DS, Li L, Xu RH, Pan ZZ, Ding PR; Written on behalf of AME Colorectal Cancer Cooperative Group.

Int J Cancer. 2019 May 1;144(9):2161-2168. doi: 10.1002/ijc.32044. Epub 2019 Jan 9.

PMID:
30521064
12.

Challenges and unanswered questions for the next decade of immune-oncology research in NSCLC.

Karachaliou N, Fernandez-Bruno M, Bracht JWP, Rosell R.

Transl Lung Cancer Res. 2018 Dec;7(6):691-702. doi: 10.21037/tlcr.2018.06.08. Review.

13.

Integrin-linked kinase (ILK) and src homology 2 domain-containing phosphatase 2 (SHP2): Novel targets in EGFR-mutation positive non-small cell lung cancer (NSCLC).

Karachaliou N, Cardona AF, Bracht JWP, Aldeguer E, Drozdowskyj A, Fernandez-Bruno M, Chaib I, Berenguer J, Santarpia M, Ito M, Codony-Servat J, Rosell R.

EBioMedicine. 2019 Jan;39:207-214. doi: 10.1016/j.ebiom.2018.11.036. Epub 2018 Nov 22.

14.

5 protein-based signature for resectable lung squamous cell carcinoma improves the prognostic performance of the TNM staging.

Martínez-Terroba E, Behrens C, Agorreta J, Monsó E, Millares L, Felip E, Rosell R, Ramirez JL, Remirez A, Torre W, Gil-Bazo I, Idoate MA, de-Torres JP, Pio R, Wistuba II, Pajares MJ, Montuenga LM.

Thorax. 2019 Apr;74(4):371-379. doi: 10.1136/thoraxjnl-2018-212194. Epub 2018 Nov 24.

PMID:
30472670
15.

Association of PALB2 Messenger RNA Expression with Platinum-Docetaxel Efficacy in Advanced Non-Small Cell Lung Cancer.

Karachaliou N, Bracht JWP, Fernandez Bruno M, Drozdowskyj A, Gimenez Capitan A, Moran T, Carcereny E, Cobo M, Domine M, Chaib I, Ramirez JL, Camps C, Provencio M, Vergnenegre A, Lopez-Vivanco G, Majem M, Massuti B, Rosell R.

J Thorac Oncol. 2019 Feb;14(2):304-310. doi: 10.1016/j.jtho.2018.10.168. Epub 2018 Nov 22.

PMID:
30472259
16.

ARID1A Gene Driver Mutations in Lung Adenocarcinomas.

Karachaliou N, Paulina Bracht JW, Rosell R.

J Thorac Oncol. 2018 Dec;13(12):e255-e257. doi: 10.1016/j.jtho.2018.07.099. No abstract available.

PMID:
30467048
17.

Low CD4/CD8 ratio in classical swine fever postnatal persistent infection generated at 3 weeks after birth.

Bohórquez JA, Wang M, Pérez-Simó M, Vidal E, Rosell R, Ganges L.

Transbound Emerg Dis. 2019 Mar;66(2):752-762. doi: 10.1111/tbed.13080. Epub 2018 Dec 9.

PMID:
30457708
18.

Cancer immunotherapy of patients with HIV infection.

Gonzalez-Cao M, Martinez-Picado J, Karachaliou N, Rosell R, Meyerhans A.

Clin Transl Oncol. 2018 Nov 17. doi: 10.1007/s12094-018-1981-6. [Epub ahead of print] Review.

PMID:
30446984
19.

EGFR exon 20 insertion in lung adenocarcinomas among Hispanics (geno1.2-CLICaP).

Cardona AF, Rojas L, Zatarain-Barrón ZL, Freitas HC, Granados ST, Castillo O, Oblitas G, Corrales L, Castro CD, Ruiz-Patiño A, Martín C, Pérez MA, González L, Chirinos L, Vargas C, Carranza H, Otero J, Rodriguez J, Rodriguez J, Archila P, Lema M, Acosta Madiedo J, Karachaliu N, Wills B, Pino LE, de Lima V, Rosell R, Arrieta O; CLICaP.

Lung Cancer. 2018 Nov;125:265-272. doi: 10.1016/j.lungcan.2018.10.007. Epub 2018 Oct 9.

PMID:
30429031
20.

LACE-Bio: Validation of Predictive and/or Prognostic Immunohistochemistry/Histochemistry-based Biomarkers in Resected Non-small-cell Lung Cancer.

Seymour L, Le Teuff G, Brambilla E, Shepherd FA, Soria JC, Kratzke R, Graziano S, Douillard JY, Rosell R, Reiman A, Lacas B, Lueza B, Aviel-Ronen S, McLeer A, Le Chevalier T, Pirker R, Filipits M, Dunant A, Pignon JP, Tsao MS; LACE-Bio Steering Committee.

Clin Lung Cancer. 2019 Mar;20(2):66-73.e6. doi: 10.1016/j.cllc.2018.10.001. Epub 2018 Oct 11.

PMID:
30414783
21.

Strategies for first-line immunotherapy in squamous cell lung cancer: are combinations a game changer?

Karachaliou N, Fernandez-Bruno M, Rosell R.

Transl Lung Cancer Res. 2018 Sep;7(Suppl 3):S198-S201. doi: 10.21037/tlcr.2018.07.02. No abstract available.

22.

Inhibition of MEK, a canonical KRAS pathway effector in KRAS mutant NSCLC.

Rosell R, Karachaliou N, Codony-Servat C, Ito M.

Transl Lung Cancer Res. 2018 Sep;7(Suppl 3):S183-S186. doi: 10.21037/tlcr.2018.03.20. No abstract available.

23.

Rhomboids and regulation of receptor tyrosine kinase ligands shedding.

Karachaliou N, Rosell R.

EBioMedicine. 2018 Nov;37:19-20. doi: 10.1016/j.ebiom.2018.09.053. Epub 2018 Oct 6. No abstract available.

24.

EGFR Amplification and Sensitizing Mutations Correlate with Survival in Lung Adenocarcinoma Patients Treated with Erlotinib (MutP-CLICaP).

Ruiz-Patiño A, Castro CD, Ricaurte LM, Cardona AF, Rojas L, Zatarain-Barrón ZL, Wills B, Reguart N, Carranza H, Vargas C, Otero J, Corrales L, Martín C, Archila P, Rodriguez J, Avila J, Bravo M, Pino LE, Rosell R, Arrieta O; Latin-American Consortium for the Investigation of Lung Cancer (CLICaP).

Target Oncol. 2018 Oct;13(5):621-629. doi: 10.1007/s11523-018-0594-x.

PMID:
30284706
25.

Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer.

Blumenthal GM, Bunn PA Jr, Chaft JE, McCoach CE, Perez EA, Scagliotti GV, Carbone DP, Aerts HJWL, Aisner DL, Bergh J, Berry DA, Jarkowski A, Botwood N, Cross DAE, Diehn M, Drezner NL, Doebele RC, Blakely CM, Eberhardt WEE, Felip E, Gianni L, Keller SP, Leavey PJ, Malik S, Pignatti F, Prowell TM, Redman MW, Rizvi NA, Rosell R, Rusch V, de Ruysscher D, Schwartz LH, Sridhara R, Stahel RA, Swisher S, Taube JM, Travis WD, Keegan P, Wiens JR, Wistuba II, Wynes MW, Hirsch FR, Kris MG.

J Thorac Oncol. 2018 Dec;13(12):1818-1831. doi: 10.1016/j.jtho.2018.09.017. Epub 2018 Sep 27. Review.

PMID:
30268698
26.

Avelumab in non-small-cell lung cancer.

Rosell R, Karachaliou N.

Lancet Oncol. 2018 Nov;19(11):1423-1424. doi: 10.1016/S1470-2045(18)30683-1. Epub 2018 Sep 24. No abstract available.

PMID:
30262188
27.

Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study.

Gadgeel S, Peters S, Mok T, Shaw AT, Kim DW, Ou SI, Pérol M, Wrona A, Novello S, Rosell R, Zeaiter A, Liu T, Nüesch E, Balas B, Camidge DR.

Ann Oncol. 2018 Nov 1;29(11):2214-2222. doi: 10.1093/annonc/mdy405.

28.

Genomic profiling in advanced stage non-small-cell lung cancer patients with platinum-based chemotherapy identifies germline variants with prognostic value in SMYD2.

Galván-Femenía I, Guindo M, Duran X, Calabuig-Fariñas S, Mercader JM, Ramirez JL, Rosell R, Torrents D, Carreras A, Kohno T, Jantus-Lewintre E, Camps C, Perucho M, Sumoy L, Yokota J, de Cid R.

Cancer Treat Res Commun. 2018;15:21-31. doi: 10.1016/j.ctarc.2018.02.003. Epub 2018 Mar 1.

29.

Atypical porcine pestivirus in wild boar (Sus scrofa), Spain.

Colom-Cadena A, Ganges L, Muñoz-González S, Castillo-Contreras R, Bohórquez JA, Rosell R, Segalés J, Marco I, Cabezon O.

Vet Rec. 2018 Nov 10;183(18):569. doi: 10.1136/vr.104824. Epub 2018 Sep 10. No abstract available.

PMID:
30201807
30.

Activation of viral defense signaling in cancer.

Gonzalez-Cao M, Karachaliou N, Santarpia M, Viteri S, Meyerhans A, Rosell R.

Ther Adv Med Oncol. 2018 Aug 29;10:1758835918793105. doi: 10.1177/1758835918793105. eCollection 2018. Review.

31.

Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis.

Duruisseaux M, Martínez-Cardús A, Calleja-Cervantes ME, Moran S, Castro de Moura M, Davalos V, Piñeyro D, Sanchez-Cespedes M, Girard N, Brevet M, Giroux-Leprieur E, Dumenil C, Pradotto M, Bironzo P, Capelletto E, Novello S, Cortot A, Copin MC, Karachaliou N, Gonzalez-Cao M, Peralta S, Montuenga LM, Gil-Bazo I, Baraibar I, Lozano MD, Varela M, Ruffinelli JC, Palmero R, Nadal E, Moran T, Perez L, Ramos I, Xiao Q, Fernandez AF, Fraga MF, Gut M, Gut I, Teixidó C, Vilariño N, Prat A, Reguart N, Benito A, Garrido P, Barragan I, Emile JF, Rosell R, Brambilla E, Esteller M.

Lancet Respir Med. 2018 Oct;6(10):771-781. doi: 10.1016/S2213-2600(18)30284-4. Epub 2018 Aug 9.

32.

Therapeutic approaches for T790M mutation positive non-small-cell lung cancer.

Attili I, Karachaliou N, Conte P, Bonanno L, Rosell R.

Expert Rev Anticancer Ther. 2018 Oct;18(10):1021-1030. doi: 10.1080/14737140.2018.1508347. Epub 2018 Aug 14. Review.

PMID:
30079781
33.

How to optimize the treatment strategy for patients with EGFR-mutant stage IA lung adenocarcinoma: an international multidisciplinary team.

Zhang Y, Shen J, Simone CB 2nd, Cappuzzo F, Fong KM, Rosell R, Chang JY, Ampollini L, Choi JI, He J, Jiang T; Written on behalf of AME Lung Cancer Cooperative Group.

J Thorac Dis. 2018 Jun;10(6):3883-3890. doi: 10.21037/jtd.2018.06.101. No abstract available.

34.

The Present and Future of Liquid Biopsies in Non-Small Cell Lung Cancer: Combining Four Biosources for Diagnosis, Prognosis, Prediction, and Disease Monitoring.

Bracht JWP, Mayo-de-Las-Casas C, Berenguer J, Karachaliou N, Rosell R.

Curr Oncol Rep. 2018 Jul 20;20(9):70. doi: 10.1007/s11912-018-0720-z. Review.

PMID:
30030656
35.

Circulating tumour DNA genomics in EGFR-mutant lung adenocarcinoma.

Rosell R, Karachaliou N.

Lancet Respir Med. 2018 Sep;6(9):649-651. doi: 10.1016/S2213-2600(18)30292-3. Epub 2018 Jul 17. No abstract available.

PMID:
30017883
36.

Combining plasma-based biosources to predict treatment response in NSCLC patients.

Bracht JWP, Berenguer J, Karachaliou N, Filipska M, Rosell R.

Ann Oncol. 2018 Sep 1;29(9):2022. doi: 10.1093/annonc/mdy246. No abstract available.

PMID:
30010765
37.

Monitoring EGFR-T790M mutation in serum/plasma for prediction of response to third-generation EGFR inhibitors in patients with lung cancer.

Morán T, Felip E, Bosch-Barrera J, de Aguirre I, Ramirez JL, Mesia C, Carcereny E, Roa D, Sais E, García Y, Blanco R, Sanchez S, Villacorta CR, Queralt C, Velarde JM, Rosell R.

Oncotarget. 2018 Jun 5;9(43):27074-27086. doi: 10.18632/oncotarget.25478. eCollection 2018 Jun 5.

38.

Gene Expression Signatures Predicting Survival and Chemotherapy Benefit in Patients with Resected Non-small-Cell Lung Cancer.

Rosell R, Karachaliou N.

EBioMedicine. 2018 Jul;33:16-17. doi: 10.1016/j.ebiom.2018.06.007. No abstract available.

39.

Migration and survival of Atlantic salmon Salmo salar smolts in a large natural lake.

Kennedy RJ, Rosell R, Millane M, Doherty D, Allen M.

J Fish Biol. 2018 Jul;93(1):134-137. doi: 10.1111/jfb.13676.

PMID:
29882213
40.

Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations.

Mok TS, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, Lee M, Linke R, Rosell R, Corral J, Migliorino MR, Pluzanski A, Sbar EI, Wang T, White JL, Wu YL.

J Clin Oncol. 2018 Aug 1;36(22):2244-2250. doi: 10.1200/JCO.2018.78.7994. Epub 2018 Jun 4.

PMID:
29864379
41.

Osimertinib in untreated epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer.

Gregorc V, Lazzari C, Karachaliou N, Rosell R, Santarpia M.

Transl Lung Cancer Res. 2018 Apr;7(Suppl 2):S165-S170. doi: 10.21037/tlcr.2018.03.19. No abstract available.

42.

Liquid biopsy for lung cancer early detection.

Santarpia M, Liguori A, D'Aveni A, Karachaliou N, Gonzalez-Cao M, Daffinà MG, Lazzari C, Altavilla G, Rosell R.

J Thorac Dis. 2018 Apr;10(Suppl 7):S882-S897. doi: 10.21037/jtd.2018.03.81. Review.

43.

Coordinated strategies for early detection of lung cancer.

Rosell R.

J Thorac Dis. 2018 Apr;10(Suppl 7):S776. doi: 10.21037/jtd.2018.04.10. No abstract available.

44.

Anti-Epidermal Growth Factor Vaccine Antibodies Enhance the Efficacy of Tyrosine Kinase Inhibitors and Delay the Emergence of Resistance in EGFR Mutant Lung Cancer Cells.

Codony-Servat J, García-Roman S, Molina-Vila MÁ, Bertran-Alamillo J, Giménez-Capitán A, Viteri S, Cardona AF, D'Hondt E, Karachaliou N, Rosell R.

J Thorac Oncol. 2018 Sep;13(9):1324-1337. doi: 10.1016/j.jtho.2018.04.030. Epub 2018 May 8.

PMID:
29751136
45.

Combination of immunotherapy with chemotherapy and radiotherapy in lung cancer: is this the beginning of the end for cancer?

Lazzari C, Karachaliou N, Bulotta A, Viganó M, Mirabile A, Brioschi E, Santarpia M, Gianni L, Rosell R, Gregorc V.

Ther Adv Med Oncol. 2018 Apr 6;10:1758835918762094. doi: 10.1177/1758835918762094. eCollection 2018. Review.

46.

STAT3 as a potential immunotherapy biomarker in oncogene-addicted non-small cell lung cancer.

Attili I, Karachaliou N, Bonanno L, Berenguer J, Bracht J, Codony-Servat J, Codony-Servat C, Ito M, Rosell R.

Ther Adv Med Oncol. 2018 Apr 2;10:1758835918763744. doi: 10.1177/1758835918763744. eCollection 2018.

47.

Clinical assessment of immune-related adverse events.

Sosa A, Lopez Cadena E, Simon Olive C, Karachaliou N, Rosell R.

Ther Adv Med Oncol. 2018 Mar 30;10:1758835918764628. doi: 10.1177/1758835918764628. eCollection 2018. Review.

48.

Science and biology drives the immune system to cure lung cancer patients: a revolution but not without challenges.

Karachaliou N, Rosell R.

Ther Adv Med Oncol. 2018 Mar 22;10:1758835918763723. doi: 10.1177/1758835918763723. eCollection 2018. No abstract available.

49.

New insights on pestivirus infections in transhumant sheep and sympatric Pyrenean chamois (Rupicapra p. pyrenaica).

Colom-Cadena A, Espunyes J, Cabezón O, Fernández-Aguilar X, Rosell R, Marco I.

Vet Microbiol. 2018 Apr;217:82-89. doi: 10.1016/j.vetmic.2018.03.003. Epub 2018 Mar 9.

PMID:
29615262
50.

The Value of Early Depth of Response in Predicting Long-Term Outcome in EGFR-Mutant Lung Cancer.

Lee CK, Lord S, Marschner I, Wu YL, Sequist L, Rosell R, Fukuoka M, Mitsudomi T, Asher R, Davies L, Gebski V, Gralla R, Mok T, Chih-Hsin Yang J.

J Thorac Oncol. 2018 Jun;13(6):792-800. doi: 10.1016/j.jtho.2018.03.010. Epub 2018 Mar 23.

PMID:
29580950

Supplemental Content

Loading ...
Support Center